NB02 for relapsed non-Hodgkin's lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new oral drug (NB02) for people with certain types of non-Hodgkin's lymphoma that have come back or not responded to at least two prior treatments. It aims to see if the drug can shrink tumors and control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 19 and 80 years old.
- You have follicular lymphoma, mantle cell lymphoma, or marginal zone lymphoma confirmed by a biopsy.
- Your lymphoma has come back or not responded after at least two prior treatments.
- You have measurable tumors on imaging scans.
- You are generally well enough to carry out daily activities (ECOG score of 2 or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
This trial tests a new drug, BT02, for people with blood cancers like leukemia, lymphoma, or multiple myeloma that have returned or not improved after treatment. The goal is to see if BT02 can help control the cancer.
This trial tests an experimental drug (HSK47977) to see how it works in people with non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to understand how the drug is processed by the body, its safety, and whether it can help shrink tumors.
This trial tests a new drug that blocks a protein helping lymphoma grow and hide from your immune system. It's for people with certain types of non-Hodgkin lymphoma that haven't improved after at least two standard treatments.
This trial is testing an investigational drug called HP-002 for people with certain types of B-cell lymphoma that have come back or not responded to prior treatment. The study aims to see if HP-002 is safe and effective, offering a new option for patients who have limited choices.
Hear when a new Non Hodgkin Lymphoma (NHL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.